The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Comprehensive characterisation of pancreatic ductal adenocarcinoma with microsatellite instability: histology, molecular pathology and clinical implications
Open accessAbstract
Objective: Recently, tumours with microsatellite instability (MSI)/defective DNA mismatch repair (dMMR) have gained considerable interest due to the success of immunotherapy in this molecular setting. Here, we aim to clarify clinical-pathological and/or molecular features of this tumour subgroup through a systematic review coupled with a comparative analysis with existing databases, also providing indications for a correct approach to the clinical identification of MSI/dMMR pancreatic ductal adenocarcinoma (PDAC). Design: PubMed, SCOPUS and Embase were searched for studies reporting data on MSI/dMMR in PDAC up to 30 November 2019. Histological and molecular data of MSI/dMMR PDAC were compared with non-MSI/dMMR PDAC and with PDAC reference cohorts (including SEER database and The Cancer Genome Atlas Research Network - TCGA project). Results: Overall, 34 studies with 8323 patients with PDAC were included in the systematic review. MSI/dMMR demonstrated a very low prevalence in PDAC (around 1%–2%). Compared with conventional PDAC, MSI/dMMR PDAC resulted strongly associated with medullary and mucinous/colloid histology (p<0.01) and with a KRAS / TP53 wild-type molecular background (p<0.01), with more common JAK genes mutations. Data on survival are still unclear. Conclusion: PDAC showing typical medullary or mucinous/colloid histology should be routinely examined for MSI/dMMR status using specific tests (immunohistochemistry, followed by MSI-PCR in cases with doubtful results). Next-generation sequencing (NGS) should be adopted either where there is limited tissue or as part of NGS tumour profiling in the context of precision oncology, acknowledging that conventional histology of PDAC may rarely harbour MSI/dMMR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000100 · Cited by 28,164
Dermyshi, E., Wang, Y., Yan, C., Hong, W., Qiu, G., Gong, X., & Zhang, T. (2017) · Neonatology · doi:10.1159/000454668 · Cited by 24,451
Meta-analysis of Observational Studies in Epidemiology<SUBTITLE>A Proposal for Reporting</SUBTITLE>
Stroup, D. F. (2000) · JAMA · doi:10.1001/jama.283.15.2008 · Cited by 20,623
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gotzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · BMJ · doi:10.1136/bmj.b2700 · Cited by 17,648
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Self-citationSpencer, P. M., Cameron, J. L., & Lin, L. (2000) · Cited by 7,202
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Boland, C. R., Thibodeau, S. N., Hamilton, S. R., Sidransky, D., Eshleman, J. R., Burt, R. W., Meltzer, S. J., Rodrı́guez-Bigas, M. A., Fodde, R., Ranzani, G. N., et al. (1998) · PubMed · Cited by 4,087
Marabelle, A., Le, D. T., Ascierto, P. A., Di Giacomo, A. M., De Jesus-Acosta, A., Delord, J.-P., Geva, R., Gottfried, M., Penel, N., Hansen, A. R., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02105 · Cited by 3,048
Kamisawa, T., Wood, L. D., Itoi, T., & Takaori, K. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00141-0 · Cited by 2,212
Self-citation
Research works printed but not linked: 8
- 10.1002/(SICI)1098-2264(199806)22:2<138::AID-GCC8>3.0.CO;2-Y · doi:10.1002/(sici)1098-2264(199806)22:2<138::aid-gcc8>3.0.co;2-y
- 10.1038/sj.bjc.6690314 · doi:10.1038/sj.bjc.6690314
- Caligo, 2000, Microsatellite alterations and K-Ras, TGFbetaRII, IGFRII and Bax mutations in sporadic cancers of the gastrointestinal tract, Oncol Rep, 7, 1371
- Nakata, 2003, Negative hMSH2 protein expression in pancreatic carcinoma may predict a better prognosis of patients, Oncol Rep, 10, 997
- 10.1016/j.cancergencyto.2008.09.008 · DOI
- 10.1136/gut.46.6.842 · doi:10.1136/gut.46.6.842
- Adsay, 2012, Ampullary region carcinomas: definition and site specific classification with delineation of four clinicopathologically and prognostically distinct subsets in an analysis of 249 cases, Am J Surg Pathol, 36, 1592, 10.1097/PAS.0b013e31826399d8 · doi:10.1097/pas.0b013e31826399d8
- 10.1007/s00428-004-1100-7 · doi:10.1007/s00428-004-1100-7
Cited by
Sotorasib in KRAS p.G12C–Mutated Advanced Pancreatic Cancer
Strickler, J. H., Satake, H., George, T. J., Yaeger, R., Hollebecque, A., Garrido-Laguna, I., Schuler, M., Burns, T. F., Coveler, A. L., Falchook, G. S., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2208470 · Cited by 527
Trivedi, P. J., Crothers, H., Mytton, J., Bosch, S., Iqbal, T., Ferguson, J., & Hirschfield, G. M. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.05.049 · Cited by 183
Gu, M., Gao, Y., & Chang, P. (2021) · Cancers · doi:10.3390/cancers13102429 · Cited by 35
PDAC as an immune evasive disease: can 3D model systems aid to tackle this clinical problem?
Narayanan, S., Vicent, S., & Ponz-Sarvisé, M. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.787249 · Cited by 24
Voutsadakis, I. A., & Digklia, A. (2023) · Chinese Clinical Oncology · doi:10.21037/cco-22-108 · Cited by 16
Metadata
- Authors
- Luchini, C., Brosens, L. A. A., Wood, L. D., Chatterjee, D., Shin, J. I., Sciammarella, C., Fiadone, G., Malleo, G., Salvia, R., Kryklyva, V., Piredda, M. L., Cheng, L., Lawlor, R. T., Adsay, V., & Scarpa, A.
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2020-04-29
- Volume
- 70
- Issue
- 1
- Pages
- 148-156
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- OpenAlex
- W3022265443
- Cited by
- 258
- References
- 51
- FWCI
- 11.55
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Funders
- KWF Kankerbestrijding (2016/10289)
- Fondazione Cariverona: Oncology Biobank Project “Antonio Schiavi” (203885/2017)
- Associazione Italiana per la Ricerca sul Cancro (12182)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comprehensive characterisation of pancreatic ductal adenocarcinoma with microsatellite instability: histology, molecular pathology and clinical implications. https://app.cochat.ai/papers/10.1136/gutjnl-2020-320726
- The paper
- Luchini, C., Brosens, L. A. A., Wood, L. D., Chatterjee, D., Shin, J. I., Sciammarella, C., Fiadone, G., Malleo, G., Salvia, R., Kryklyva, V., Piredda, M. L., Cheng, L., Lawlor, R. T., Adsay, V., & Scarpa, A. (2021). Comprehensive characterisation of pancreatic ductal adenocarcinoma with microsatellite instability: histology, molecular pathology and clinical implications. Gut. https://doi.org/10.1136/gutjnl-2020-320726
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.